QQQ   432.04 (+0.23%)
AAPL   169.41 (-1.90%)
MSFT   416.29 (+0.64%)
META   502.25 (+0.40%)
GOOGL   154.80 (-0.04%)
AMZN   183.90 (+0.15%)
TSLA   156.90 (-2.84%)
NVDA   875.29 (+1.78%)
AMD   163.42 (+1.93%)
NIO   3.84 (-1.29%)
BABA   69.94 (-0.96%)
T   16.05 (-1.17%)
F   12.20 (-0.25%)
MU   121.23 (-0.12%)
GE   155.55 (+1.20%)
CGC   6.89 (-1.29%)
DIS   114.17 (+1.08%)
AMC   2.78 (+12.55%)
PFE   25.81 (-0.39%)
PYPL   63.99 (+0.76%)
XOM   118.68 (-0.84%)
QQQ   432.04 (+0.23%)
AAPL   169.41 (-1.90%)
MSFT   416.29 (+0.64%)
META   502.25 (+0.40%)
GOOGL   154.80 (-0.04%)
AMZN   183.90 (+0.15%)
TSLA   156.90 (-2.84%)
NVDA   875.29 (+1.78%)
AMD   163.42 (+1.93%)
NIO   3.84 (-1.29%)
BABA   69.94 (-0.96%)
T   16.05 (-1.17%)
F   12.20 (-0.25%)
MU   121.23 (-0.12%)
GE   155.55 (+1.20%)
CGC   6.89 (-1.29%)
DIS   114.17 (+1.08%)
AMC   2.78 (+12.55%)
PFE   25.81 (-0.39%)
PYPL   63.99 (+0.76%)
XOM   118.68 (-0.84%)
QQQ   432.04 (+0.23%)
AAPL   169.41 (-1.90%)
MSFT   416.29 (+0.64%)
META   502.25 (+0.40%)
GOOGL   154.80 (-0.04%)
AMZN   183.90 (+0.15%)
TSLA   156.90 (-2.84%)
NVDA   875.29 (+1.78%)
AMD   163.42 (+1.93%)
NIO   3.84 (-1.29%)
BABA   69.94 (-0.96%)
T   16.05 (-1.17%)
F   12.20 (-0.25%)
MU   121.23 (-0.12%)
GE   155.55 (+1.20%)
CGC   6.89 (-1.29%)
DIS   114.17 (+1.08%)
AMC   2.78 (+12.55%)
PFE   25.81 (-0.39%)
PYPL   63.99 (+0.76%)
XOM   118.68 (-0.84%)
QQQ   432.04 (+0.23%)
AAPL   169.41 (-1.90%)
MSFT   416.29 (+0.64%)
META   502.25 (+0.40%)
GOOGL   154.80 (-0.04%)
AMZN   183.90 (+0.15%)
TSLA   156.90 (-2.84%)
NVDA   875.29 (+1.78%)
AMD   163.42 (+1.93%)
NIO   3.84 (-1.29%)
BABA   69.94 (-0.96%)
T   16.05 (-1.17%)
F   12.20 (-0.25%)
MU   121.23 (-0.12%)
GE   155.55 (+1.20%)
CGC   6.89 (-1.29%)
DIS   114.17 (+1.08%)
AMC   2.78 (+12.55%)
PFE   25.81 (-0.39%)
PYPL   63.99 (+0.76%)
XOM   118.68 (-0.84%)
OTCMKTS:ABCZY

Abcam (ABCZY) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
$19.40
$19.40
52-Week Range
N/A
Volume
5,400 shs
Average Volume
4,712 shs
Market Capitalization
$3.98 billion
P/E Ratio
N/A
Dividend Yield
0.36%
Price Target
N/A
ABCZY stock logo

About Abcam Stock (OTCMKTS:ABCZY)

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

ABCZY Stock News Headlines

Abcam appoints Markus Lusser as new President
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Abcam shareholders approve $5.7 billion Danaher deal
Abcam founder ends fight to block takeover
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Abcam plc Statement on Dr. Jonathan Milner’s Announcement
Abcam founder Jonathan Milner renews clear-out bid
See More Headlines
Receive ABCZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Industrial Inorganic Chemicals
Sub-Industry
N/A
Current Symbol
OTCMKTS:ABCZY
Previous Symbol
NASDAQ:ABCZY
CIK
N/A
Fax
N/A
Employees
1,492
Year Founded
1998

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$336.37 million

Miscellaneous

Free Float
N/A
Market Cap
$3.98 billion
Optionable
Not Optionable
Beta
1.29

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Alan Thomas Hirzel BS (Age 52)
    MS, MBA, CEO & Exec. Director
  • Mr. Michael Shaun Baldock (Age 54)
    CFO & Director
  • Dr. Jonathan Simon Milner (Age 55)
    Co-Founder & Non-Exec. Deputy Chairman
  • Mr. Mark Dermody
    Interim CIO
  • James Staveley
    VP of Investor Relations

ABCZY Stock Analysis - Frequently Asked Questions

Is Abcam a good dividend stock?

Abcam (OTCMKTS:ABCZY) pays an annual dividend of $0.07 per share and currently has a dividend yield of 0.36%.
Read our dividend analysis for ABCZY.

How do I buy shares of Abcam?

Shares of ABCZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Abcam have any subsidiaries?
The following companies are subsidiares of Abcam: Abcam (US) Ltd., Abcam Trading (Shanghai) Co. Ltd., Abcam US Group Holdings Inc., and Epitomics Inc.
Read More
This page (OTCMKTS:ABCZY) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners